Overview
NICE is unable to make a recommendation on pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because the company did not provide an evidence submission.
Last reviewed: 02 April 2025
Next review: We will review this decision if the company decides to make a submission.